SS Innovations International (NASDAQ: SSII) presented its surgical robotics platform in a series of remote operations during October medical conferences in Spain and India, including a robotic-assisted cardiac procedure performed by a surgeon approximately 7,500 miles from the patient. The demonstrations featured the company's SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, SS Innovations Chairman and Chief Executive Officer Dr. Sudhir Srivastava remotely performed an atrial septal defect procedure on a patient located in Bengaluru, India. The event underscored the system's capability to enable long-distance telesurgery, a promising approach for delivering specialized care to underserved regions.
In addition, four robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric and gynecological procedures. These demonstrations illustrated the versatility of the SSi Mantra across multiple surgical disciplines.
The company reported that 205 telesurgeries have been performed with the SSi Mantra system as of October 23, 2026, including cardiac procedures. This milestone reflects growing experience with remote robotic surgery, which could extend specialist expertise beyond major medical centers. However, widespread adoption will depend on clinical validation, connectivity and regulatory requirements.
SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027. The timeline remains subject to the FDA's review. FDA clearance would mark a significant step toward commercial availability in the United States, potentially broadening access to advanced robotic surgery.
The company's showcase at international events highlights its efforts to advance surgical robotics and telemedicine. For investors and industry observers, the demonstrations and the progress toward FDA clearance are key indicators of the company's trajectory in the competitive surgical robotics market. The potential impact extends to patients in remote areas who could benefit from expert surgical care without the need for travel.
For more details on SS Innovations, visit SS Innovations (NASDAQ: SSII). The original release is available at www.newmediawire.com, and additional information can be found at https://ibn.fm/EZFDT. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
